First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu-and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra-and extramedullary disease

Journal of Nuclear Medicine

Volumn 57, Issue 2, 2016, Pages 248-251

  Herrmann, Ken ^a,b   Schottelius, Margret ^c   Lapa, Constantin ^a   Osl, Theresa ^c   Poschenrieder, Andreas ^c   Hänscheid, Heribert ^a   Lückerath, Katharina ^a   Schreder, Martin ^a   Bluemel, Christina ^a   Knott, Markus ^a   Keller, Ulrich ^c,d   Schirbel, Andreas ^a   Samnick, Samuel ^a   Lassmann, Michael ^a   Kropf, Saskia ^e   Buck, Andreas K ^a   Einsele, Hermann ^a   Wester, Hans Juergen ^c   Knop, Stefan ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e SCINTOMICS GMBH   (Germany)

Author keywords

CXCR4; Endoradiotherapy; Multiple myeloma; Pentixather

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; LIGAND; LUTETIUM 177; YTTRIUM 90; 177LU-PENTIXATHER; 90Y-PENTIXATHER; ANTINEOPLASTIC AGENT; PEPTIDE; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW RESCUE; CANCER RADIOTHERAPY; CASE REPORT; DISEASE DURATION; DOSIMETRY; FEMALE; HUMAN; MALE; METASTASIS; MULTIPLE MYELOMA; PLASMA CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; TUMOR GROWTH; BONE MARROW TRANSPLANTATION; DRUG EFFECTS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RADIOMETRY; SCINTISCANNING; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM METASTASIS; PEPTIDES; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTORS, CXCR4; TREATMENT OUTCOME;

EID: 84958630177     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.167361     Document Type: Article

References (20)

1. de la Puente P, Muz B, Azab F, Luderer M, Azab AK. Molecularly targeted therapies in multiple myeloma. Leuk Res Treatment. 2014;2014:976567.
2. Röllig C, Knop S, Bornhauser M. Multiple myeloma. Lancet. 2015;385:2197-2208.
3. Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32:587-600.
4. Prideaux SM, Conway O'Brien E, Chevassut TJ. The genetic architecture of multiple myeloma. Adv Hematol. 2014;2014:864058.
5. Brioli A, Melchor L, Cavo M, Morgan GJ. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol. 2014;165:441-454.
6. Peled A, Tavor S. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics. 2013;3:34-39.
7. Ratajczak MZ, Serwin K, Schneider G. Innate immunity derived factors as external modulators of the CXCL12-CXCR4 axis and their role in stem cell homing and mobilization. Theranostics. 2013;3:3-10.
8. Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013;49:219-230.
9. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009;23:43-52.
10. Cojoc M, Peitzsch C, Trautmann F, Polishchuk L, Telegeev GD, Dubrovska A. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther. 2013;6:1347-1361.
11. Demmer O, Gourni E, Schumacher U, Kessler H, Wester HJ. PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem. 2011;6: 1789-1791.
12. 68Galabeled highly specific targeted contrast agent. J Nucl Med. 2011;52:1803-1810.
13. Wester HJ, Keller U, Schottelius M, et al. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics. 2015;5:618-630.
14. Philipp-Abbrederis K, Herrmann K, Knop S, et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015;7:477-487.
15. 177Lu-and 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):13S-17S.
16. 177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:214-222.
17. Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800-816.
18. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473.
19. Munshi NC, Anderson KC. Minimal residual disease in multiple myeloma. J Clin Oncol. 2013;31:2523-2526.
20. Tamas K, Domanska UM, Dijk TH, et al. CXCR4 and CXCL12 expression in rectal tumors of stage IV patients before and after local radiotherapy and systemic neoadjuvant treatment. Curr Pharm Des. 2015;21:2276-2283.